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Background/Objective. Hydrocortisone, administered to ventilated preterm neonates to facilitate extubation, has no adverse long-
term eﬀects, but short-term pulmonary eﬀects have not been described previously. In the present study, we analyzed eﬀects of
hydrocortisone on ventilator settings and FiO2 in ventilator-dependent preterm infants. Patients and Methods. Fifty-ﬁve preterm
children were included in this retrospective cohort study. Hydrocortisone was administered at a postnatal age of >7 days to treat
chronic lung disease (CLD). Ventilator settings before and after hydrocortisone administration were recorded as well as FiO2 at
36 weeks’ gestational age. Presence of cerebral palsy was assessed at a mean corrected age of 24.1 months. Results. Hydrocortisone
administered at a median postnatal age of 14 days signiﬁcantly reduced FiO2 from a median of 0.39 to 0.30, mean airway pressure
(MAP) from a median of 10.0cm H2Ot o7 . 6c mH 2O, and PaCO2 from a median of 53.5mmHg to 47mmHg. Extubation was
achieved in all patients. CLD at 36 weeks was present in 11 of the 52 patients (21.1%). None developed cerebral palsy. Conclusions.
Hydrocortisone was eﬀective in reducing theFiO2,MAP ,a n dP a CO 2 and facilitated extubation. Hydrocortisone was not associated
with cerebral palsy.
1.Introduction
Bronchopulmonary dysplasia (BPD) or chronic lung disease
(CLD) was ﬁrst described in 1967 as a severe form of
lung disease in premature infants with severe respiratory
distress syndrome, who received prolonged mechanical ven-
tilation and high concentrations of oxygen [1]. Improved
mechanically ventilatory strategies, and the introduction
of antenatal glucocorticosteroids and postnatal surfactant
treatment, have greatly reduced postnatal lung injury and
increased survival of premature infants, resulting in a re-
ported incidence of CLD of 8%–35% [2, 3].
Still, CLD remains a signiﬁcant problem in neonatal in-
tensive care because of the signiﬁcant cause of mortality,
morbidity, and prolonged hospitalization [3]. Since inﬂam-
mation plays an important role in the pathogenesis of
CLD [3, 4], glucocorticosteroids, mainly dexamethasone,
have been widely used to reduce CLD. Numerous studies
show that dexamethasone improves short-term respiratory
function, leading to a reduction in supplementary oxygen
requirements and earlier extubation [5–7].
Despite its positive eﬀect on neonatal lung function,
dexamethasone therapy exerts several acute adverse eﬀects,
such as hyperglycemia, hypertension, and left ventricular
hypertrophy. Concerns about the long-term beneﬁts of this
steroid in ventilator-dependent infants arose in the 1970s
when it became clear that there was an increased risk of
cerebralpalsyafterpostnataldexamethasoneexposure[8].In
recentyears,scientiﬁcevidencehasaccumulatedonthelong-
term negative eﬀects of neonatal dexamethasone treatment
[9–11].
In contrast to other neonatal intensive care units
(NICUs) in the Netherlands, the Wilhelmina Children’s
Hospital has historically always used the corticosteroid hy-
drocortisone instead of the more potent dexamethasone to
treat ventilator-dependent preterm infants at risk for CLD2 International Journal of Pediatrics
because of fewer adverse eﬀects and the apparently similar
clinical beneﬁts [12, 13]. However, until now no studies have
described the short-term eﬀects of hydrocortisone treatment
on respiratory function.
The purpose of this retrospective study is to analyze the
immediate eﬀect of hydrocortisone therapy on mechanical
ventilation settings in ventilator-dependent preterm infants.
2. Patientsand Methods
The study population presented in this retrospective cohort
study consists of patients who were born after a gestational
age of ≤32 weeks and/or a birth weight of ≤1500 grams
between January 1, 2003 and December 31, 2007. These
patients were consecutively admitted soon after birth over a
periodofﬁveyearstotheNeonatalIntensive Care Unit ofthe
Wilhelmina Children’s Hospital, a tertiary referral centre.
One hundred and twenty-seven children born after a
pregnancy of ≤32 weeks and/or with a birth weight of
≤1500g had been treated postnatally with corticosteroids for
several reasons.
Nine patients received besides hydrocortisone also dex-
amethasone (two during part of their treatment in another
hospital and seven prior to extubation) and were excluded to
avoid contamination of hydrocortisone treatment eﬀects.
Onehundredandeighteeninfantsbornafterapregnancy
of ≤32 weeks and/or with a birth weight of ≤1500g received
hydrocortisone treatment. Two patients received hydrocor-
tisone as a replacement therapy for their congenital adrenal
hyperplasia. Fifty-three patients received hydrocortisone to
treat hypotension.
Sixty-eight patients were treated with hydrocortisone to
facilitate extubation. In one case, the attending neonatologi-
cal staﬀ decided to stop treatment after one day of hydrocor-
tisone treatment because of severe respiratory insuﬃciency
and the poor prognosis based on pulmonary hypoplasia as a
result of PPROM.
In twelve children treated with nasal continuous positive
airwaypressure(nCPAP)afterhavingbeenventilated,hydro-
cortisone was administered in order to avoid re-intubation.
These thirteen children were excluded.
Four infants in whom hydrocortisone treatment was
started while being ventilated died in neonatal period on day
13, 18, 22, and 63; one of bullous emphysema and three of
severe chronic lung injury with in one case in combination
with a metabolic disorder of unspeciﬁed origin. These four
children were not excluded.
Fifty-ﬁve out ofthe 118 children (46.6%) received hydro-
cortisone treatment for prolonged ventilator dependency.
2.1. Eligibility Criteria. Infants were eligible for the study if
they met the following criteria: (1) gestational age ≤32 weeks
and/or birth weight ≤1500g, (2) ventilator dependency
based on signs of chronic lung disease, (3) hydrocortisone
treatment, and (4) availability of data as deﬁned in the study
protocol. Infants who were treated with dexamethasone, for
example, after referral from other NICUs, were excluded as
well as infants who were not ventilator dependent but had
CPAP for respiratory support.
2.2. Study Protocol
2.2.1. Demographic Variables. The following characteristics
were retrospectively collected: gestational age (weeks), birth
weight (grams), gender, small for gestational age <p2.3
(SGA), administration of antenatal steroids, premature pro-
longed rupture of membranes (>24 hours, PPROM), Apgar
scores, and surfactant therapy.
2.2.2. Ventilator Settings. The charts of all preterm infants
born after a pregnancy of ≤32 weeks and/or a birth weight
≤1500g receiving hydrocortisone treatment were systemati-
cally reviewed for ventilation dependency. It was clear that in
several days before the start of hydrocortisone treatment, no
positive changes were seen in ventilator settings.
Data on ventilator settings were recorded within an
hour before the start of hydrocortisone therapy and again
one day and two days later: inspiratory oxygen fraction
(FiO2), mean airway pressure (MAP; cm H2O), and arterial
PaCO2(mmHg). Duration of mechanical ventilation and
oxygen requirements at postmenstrual age of 36 weeks were
documented.
2.2.3. Ventilation Policy. The targeted level of oxygen satura-
tionandPaCO2 was88–93%and45–60mmHg,respectively.
2.2.4. Hydrocortisone Treatment. Generally, hydrocortisone
was started when the postnatal age was at least more than 7
days and the child was ventilator-dependent with increasing
oxygen requirements (FiO2 more than 0.40), prolonged
dependency of extra oxygen (FiO2 of more than 0.40) based
on chronic lung disease as evidenced by repeated pulmonary
X-rays. Echocardiography was performed in all patients to
exclude a hemodynamically signiﬁcant patent ductus arte-
riosus before considering hydrocortisone. Hydrocortisone
was given at a starting dose of 5mg/kg/day tapering oﬀ
to 1.25mg/kg/day over a 22-day period. Depending on the
response to therapy, steroid treatment was either prolonged
or repeated. Weaning from the ventilator occurred on the
basis of clinical condition and blood gases.
Postnatal age at start of treatment, number of days
treated with hydrocortisone, and hydrocortisone dose (mg/
kg mean weight; mean weight: weight at the end of the
treatment plus weight at the start of treatment divided by
two) over the treatment period were recorded.
2.2.5. Neurological Outcome. Infants were evaluated with a
standardized neurologic examination at corrected ages of
0, 6, 15, and 24 months using items from the methods of
Amiel-Tison and Grenier [14], Touwen [15], and a Griﬃths’
assessment [16]. Each child was examined for the presence
of cerebral palsy. If present, neuromotor abnormalities
including tone abnormalities/presence and type of cerebral
palsy were recorded. Cerebral palsy was deﬁned as a non-
progressive central nervous system disorder characterized by
abnormalmuscletoneinatleastoneextremityandabnormal
control of movement and posture [8, 17].International Journal of Pediatrics 3
Table 1: Patient characteristics.
Characteristics Total (n = 55) %
Gestational age (wk)a 27.3±1.4
Birth weight (g)a 924±231
Genderc
Female:male 17:38
SGA (<p2.3)c 47 . 3
Antenatal steroidsc 47 85.5
PROM > 24 hc 12 21.8
Apgar scoreb
At 1min 6 (1–10)
At 5min 8 (1–10)
Mortalityc 4
Postnatal age at death (days) 13, 18, 22, 63
Inotropesc 38 69.1
Patent ductus arteriosusc 31 56.4
Indometacin 30 96.8
Surgery 12 # 38.7
NECc 23 . 6
NEC surgery requirementc 2 100
IVHc 21 38.2
Grades I-II 14 —
Grades III-IV 7 —
Cystic PVLc(grade II) 1 —
Data are shown as amean ± SD, bmedian (range) or cn.
SGA: small for gestational age, PROM: premature rupture of membranes,
NEC: necrotizing enterocolitis, IVH: intraventricular haemorrhage, and
PVL: periventricular leukomalacia.
#In one case indometacin therapy was contraindicated because of IVH.
2.3. Study Endpoints. Primary outcome measures were ven-
tilator settings after day 1 and day 2 of treatment, duration
of mechanical ventilation, successful extubation after start
of hydrocortisone, CLD at postmenstrual age of 36 weeks,
mortality, and development of cerebral palsy.
2.4.StatisticalAnalysis. Dataaresummarizedasmeans ±SD
or median and ranges. Data on respiratory function of day
0, day 1, and day 2, that is, FiO2, MAP, and PaCO2 were
pairwise compared using Wilcoxon rank sum. A P-value <
0.05 was considered statistically signiﬁcant. All analyses were
performed using SPSS version 15.0.1 for windows (SPSS,
Chicago, Il, USA).
3. Results
Fifty-ﬁve ventilation-dependent children fulﬁlled the inclu-
sion criteria and were included in the present retrospective
study. Table 1 shows the most important patient characteris-
tics whereas Table 2 shows respiratory characteristics.
Hydrocortisone was initiated at a median age of 11 days
(Table 2 and Figure 1).
Median duration of hydrocortisone treatment was 21
days. In 52 out of 55 hydrocortisone-treated patients, the
cumulative dose/kg mean weight could be calculated (mean
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Figure 1: Age at start treatment with hydrocortisone.
Table 2: Respiratory characteristics.
Characteristics Total (n = 55) %
Duration of ventilation (days)b 15.0 (5–69) ∗
HFOV before treatmentc 34.0 61.8
Postnatal age at start of HC (days)b 11 (7–44)
Duration of HC (days)d 21.0 (9.0)
HC dose (mg/kg mean weight)d 56.9 (28.2)
Extubation after start HC (days)d 4.0 (4.0)
IRDSc
Grades I-II 23 41.8
Grades III-IV 32 58.2
Surfactantc
No 6 10.9
Yes 49 89.1
Pneumothoraxc 12 21.8
Data are shown as bmedian (range), cn or dmedian (interquartile range).
HFOV: high frequency oscillation ventilation; HC: hydrocortisone; IRDS:
infant respiratory distress syndrome.
∗In one case it took 69 days to wean the child from ventilator because of
ongoing sepsis.
weight: weight at the end of treatment plus weight at the
start of treatment divided by two). Median cumulative
hydrocortisone dose was 56.9mg/kg mean weight.
3.1. Respiratory Eﬀects. All 55 patients, who received hydro-
cortisone while being ventilated, could be successfully extu-
bated at a median age of 4 days. In one case, it was hard to
wean the child from the ventilator because of intercurrent
periods of Staphylococcus epidermidis sepsis. This child was
eventually weaned after 69 days.
Treatment with hydrocortisone was potent in reducing
theneedforextraoxygen(Figure 2).Therewasasigniﬁcantly
reduced requirement for oxygen after day 2 (P-value =0.001)
following start of hydrocortisone treatment and between day
1 and day 2 after start of hydrocortisone (P-value = 0.001).4 International Journal of Pediatrics
Day 2 Day 1 Day 0
0.7
0.6
0.5
0.4
0.3
0.2
∗
P<0.05 NS
P<0.05
F
i
O
2
(
f
r
a
c
t
i
o
n
)
Figure 2: Values of oxygen requirement (inspirational oxygen
fraction (FiO2)) on day 0 (baseline), day 1, and day 2 following
treatment with hydrocortisone (HC). ∗P<0.05 versus day 0
(baseline) and day 1. NS = non signiﬁcant. FiO2 signiﬁcantly
decreases after day 2 compared with day 0 (baseline) and between
day 1 and day 2.
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Figure 3: Values of Mean Airway Pressure (cm H2O) on day 0
(baseline), day 1, and day 2 following treatment with hydrocorti-
sone (HC). ∗P<0.05 versus day 0 (baseline) and day 1. Mean
airwaypressuresigniﬁcantlydecreasesonday1andday2compared
with day 0 (baseline).
No signiﬁcant reduced oxygen requirement was seen after
one day (P-value = 0.006).
Maximal eﬀect of hydrocortisone treatment on MAP
was seen after day 1 after start treatment (Figure 3). This
eﬀect was signiﬁcant with a P-value of 0.002. Furthermore, a
signiﬁcanteﬀectwasalsoseenafterday2afterstarttreatment
(P-value < 0.001) and between day 1 and day 2 (P-value <
0.001).
Hydrocortisone treatment had a maximal eﬀect on
PaCO2 one day after start treatment (P-value < 0.001)
(Figure 4). No signiﬁcant eﬀect on PaCO2 was seen between
day 1 and 2 after start hydrocortisone (P-value = 0.453).
After a gestational age of 36 weeks, 11 children (21.1%)
required supplemental oxygen. Four children died before
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Figure 4: Values of PaCO2(mmHg) on day 0 (baseline), day 1, and
day 2 following treatment with hydrocortisone (HC). ∗P<0.05
versus day 0 (baseline) and day 1. NS = non signiﬁcant. PaCO2
signiﬁcantly decreases on day 1 and day 2 compared with day 0
(baseline).
gestationalageof36weeks,andinonesurvivingcasesupple-
mental oxygen requirement was not noted.
3.2. Neurodevelopmental Followup. Fifty-ﬁve ventilation-
dependent children were included in this retrospective study.
Of these, four were known to have died during neonatal
period, leaving ﬁfty-one patients available for followup at
24 months of corrected age (mean 24.1±0.27 months).
Standardized neurologic examination revealed that none of
the 51 patients developed cerebral palsy.
4. Discussion
Our ﬁndings suggest that moderately early hydrocortisone
therapy, in the dose mentioned, leads to a signiﬁcant re-
duction in oxygen requirement (FiO2), PaCO2,a n dm e a n
airway pressure in ventilator-dependent preterm infants
more than 7 days old who were at risk for CLD.
Several studies indicate that low-dose dexamethasone
administrationaftertheﬁrstweekoflifesigniﬁcantlyreduces
the short-term pulmonary eﬀects as failure to extubation
and days of mechanical ventilation in ventilator-dependent
preterm infants [5, 7, 18].
The study of Doyle et al. reported that dexamethasone
(0.89mg/kg/10 days) given at a median treatment age of
23 days to ventilator-dependent extremely low birthweight
infants improved ventilator and oxygen requirements sub-
stantially and shortened the duration of intubation. There
was little evidence for a reduction in either the mortality rate
or the rate of oxygen dependency at 36 weeks [5].
Another study found that moderately early low-dose
dexamethasone therapy for 7 days (tapering course, 0.2 to
0.1mg/kg) had comparable beneﬁcial eﬀects to a high dose
regimen. In both groups of infants (gestational age 24–
30 weeks; birth weight 550–1290g), FiO2 and MAP were
signiﬁcantly reduced [18].
A recent systematic review of 16 randomized, placebo-
controlled trials (RTCs) including 1136 randomly assigned
ventilated preterm infants more than 7 days of age assessed
the eﬀects of diﬀerent cumulative dexamethasone doses onInternational Journal of Pediatrics 5
CLD and neurodevelopmental outcome. This paper con
cludedthathighercumulativedexamethasonedoses(≥4mg/
kg) administered after the ﬁrst week of life may decrease the
relative risk for the combined outcome CLD or mortality.
The risk of mortality or cerebral palsy was decreased by 6.2%
for each incremental mg/kg cumulative dexamethasone dose
when administered between 7–14 days of live. Furthermore,
a signiﬁcant reduction in short-term pulmonary eﬀects as
failure to extubation on day 3 and 7 and days of mechanical
ventilation was seen in patients treated with dexamethasone
after 7 days of live. These outcomes were independent of the
cumulative dexamethasone dose [19].
Over the past years, concerns on the long-term neuro-
developmental consequences after dexamethasone therapy
arose, when followup of a randomized controlled trial
revealed a marked increase in neurodevelopmental dysfunc-
tion in neonates treated with dexamethasone compared with
controls [11]. Since then, more reports of long-term negative
neurodevelopmental sequelae have been published [10, 20,
21], and as a result The American Academy of Pediatrics
stated in 2002 [22] that postnatal steroid administration,
outside clinical trials, should be limited to “exceptional
clinical circumstances”. In addition, a revised statement was
issued by The American Academy of Pediatrics stating that
current evidence is insuﬃcient to make a recommendation
regarding treatment with other glucocorticosteroids [23].
The long-term negative eﬀects of dexamethasone neces-
sitate a search for alternatives in the treatment of neonates
with chronic lung disease. One of the possibilities frequently
suggested in recent literature is the glucocorticosteroid
hydrocortisone.
Few studies [12, 24–26]h a v ei n v e s t i g a t e dt h eu s eo f
hydrocortisone for treatment of CLD in premature infants
anddescribedlong-termneurologicaloutcomes,reviewedby
Rademaker et al. [13].
Van der Heide-Jalving et al. retrospectively studied
in a group of 25 preterm infants (mean gestational age
28.3 weeks; mean birth weight 1040g) the eﬀect of high-
dose hydrocortisone on neurodevelopmental outcome. No
signiﬁcant diﬀerences were detected between the matched
control group and hydrocortisone group with respect to neu-
rological outcome, psychomotor development, and school
performanceatage5–7years.However,childrentreatedwith
dexamethasone had a signiﬁcantly less favourable school
performance than their controls [12].
Another retrospective matched cohort study, Karemaker
et al., compared behavioural outcome and motor skills
in 192 preterm infants who neonatally either received
dexamethasone or hydrocortisone for chronic lung disease.
Dexamethasone- and hydrocortisone-treated groups were
compared with a reference group and a group treated only
antenatally with betamethasone. The groups were matched
for gestational age, birth weight, gender, rate of respiratory
distress syndrome, and rate of peri/intraventricular haemor-
rhage. At school age (7–10 years), the children treated with
dexamethasone had a worse neurodevelopmental outcome
than the reference group and betamethasone group, whereas
the outcome of hydrocortisone-treated children did not
diﬀer from these two groups [24].
A large cohort study on long-term neurodevelopmental
outcome in children following neonatal hydrocortisone
treatment was reported in 2007 [25]. In this study, 226
preterm children (62 had been treated postnatally with
hydrocortisone for CLD and 164 had not been treated
with steroids) were followed up for 8 years. As this study
was nonrandomized and treated children were generally
sicker than untreated children, adjustments were made for
gestational age, birth weight, gender, need for mechanical
ventilationandsmall-for-gestationalage.Nodiﬀerenceswere
found in neurocognitive and motor performance between
the two groups. Incidence of cerebral palsy and brain lesions
on MRI was also similar.
Watterberg et al. reported that early low-dose hydrocor-
tisone therapy for prophylaxis of early adrenal insuﬃciency
to prevent bronchopulmonary dysplasia did not increase
the incidence of cerebral palsy in extremely low birth
weight infants. Treated infants had indicators of improved
developmental outcome at 18 to 22 months’ corrected age
[26].
Recently, a prospective study was performed to evaluate
the brain growth at term in preterm infants who did
receive neonatal hydrocortisone for CLD. Thirty-eight pre-
term infants (n = 19 hydrocortisone, n = 19 controls)
were matched for gestational age at birth. There were no
diﬀerencesincerebraltissuevolumesbetweenthetwogroups
at term equivalent age. In conclusion, no eﬀect on brain
growth was shown after treatment with hydrocortisone for
CLD [27].
Our study supports the suggestion that hydrocortisone
is not associated with cerebral palsy at 24 months adjusted
age. According to ﬁndings of a recent study, we would have
expected to ﬁnd 2–5 cases of CP in our patients [28].
In 2010, Doyle et al. reviewed systematically the data
from eight randomised controlled trials in newborn infants
where hydrocortisone was compared with placebo to estab-
lish the balance between risks and beneﬁts of hydrocortisone
in newborn infants in the prevention or treatment of CLD
[29]. In all eight trials, treatment was started in the ﬁrst week
of life; there were no trials of treatment started in infants
who were chronically ventilated-dependent after the ﬁrst
week of life. A meta-analysis demonstrated little evidence to
support the use of hydrocortisone (ranging in dose from 5
to 15mg/kg) to prevent CLD; there were no improvements
in important outcomes of mortality, or of rates in CLD or
home oxygen dependence.
To our knowledge, no studies are performed that assess
the short-term pulmonary eﬀects following hydrocortisone
treatment. Our study provides the ﬁrst evidence that, besides
dexamethasone, hydrocortisone also facilitates extubation,
reduces oxygen and ventilator requirements. Since short-
term pulmonary eﬀects of dexamethasone and hydrocor-
tisone are clinical comparable, and dexamethasone has
proven long-term negative adverse eﬀects, studies to use
hydrocortisone in preterm ventilator-dependent infants at
risk for CLD are warranted.6 International Journal of Pediatrics
4.1. Limitations of the Study. The present study has also
limitations. The primary limitation of our study is the lack of
acontrolgroup.Thislackismainlyrelatedtoitsretrospective
nature.
Furthermore,thedataobtainedinthisstudywerelimited
by the fact that we performed a retrospective cohort study
and not a randomized prospective study.
The sample size of our study population is small. The
ﬁfty-ﬁve patients in this study were born with a gestational
age ≤32 weeks and/or birthweight of ≤1500 grams admitted
over a period of ﬁve years to our NICU. Only a relatively
small group fulﬁlled our inclusion criteria, a large group
receivedhydrocortisoneforotherreasonsthanweaningfrom
the ventilator.
Bearing in mind the above considerations, the results of
this study still provides useful information.
Weareconvincedthatthisistheﬁrststeptowardsconsid-
ering hydrocortisone as a therapy for prolonged ventilator-
dependent children at risk for CLD. Finally, the results of
the present study urge for a large double-blind randomized
controlled trial on hydrocortisone versus placebo treatment
for ventilator-dependent children at risk for CLD to clarify
the discussion about which corticosteroid (dexamethasone
or hydrocortisone) is safer for treatment of preterm infants
with chronic lung injury.
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